Back to Agenda
Session 5: Inspections and Audits and Quality Management Systems
Session Chair(s)
Brian Edwards, DrMed
Vice President
International Society of Pharmacovigilance, United Kingdom
The QPPV is important in directing the interpretation of pharmacovigilance legislation and guidance. QPPVs have considerable flexibility but the basis of the decision must be transparent and properly documented. QPPVs must be able to explain the rationale of why a process is set up in a certain way or whether further changes are required to produce a compliant process. Challenges for quality include obtaining cross-functional ownership of issues and ensuring that all root causes remained addressed by corrective and preventive action plans. This session will explore the different experiences of the MAHs systems that both inspectors and auditors have recently had, how their activities have been supported by the QPPV and how they might expect the MAH to approach human error, communications between departments and other options, apart from audit, that the MAH might use to assess quality.
Speaker(s)
Identifying and Managing Non-Compliance in the PV System
Kiernan Trevett, MSc
Genentech, A Member of the Roche Group, United States
Quality Policy Lead
Expectations on Inspections
Magnus Ysander, MD
AstraZeneca, Sweden
EU & UK QPPV & Head Pharmacovigilance Excellence
PV Quality Management at the Affiliate
Leen Verbert
GlaxoSmithKline Biologicals, Belgium
PV QA & Training Director
Have an account?